Arbutus Biopharma Corporation

The end of the first quarter of 2025 and the beginning of Q2 have been rough for public biopharma companies, with the closely watched XBI fund falling first in reaction to layoffs at the US Food and D

Vir Biotechnology, Inc. brought on a new CEO in 2023 and in 2024 it is bringing on a new therapeutic area, while announcing its second round of job cuts in less than a year. The infectious disease sp

After a month and a half initial public offering drought, two biopharmaceutical companies – Neumora Therapeutics, Inc. and RayzeBio, Inc. – launched IPOs in the US and grossed $561m combined on 14

With no RNA interference-based therapy approved in China yet, Sirnaomics, Inc. is seeking to gain an edge over a growing number of local competitors by targeting cancer indications. With dual headqu